News Release

View printer-friendly version
<< Back

DURECT Corporation Presenting at the Lazard 1st Annual Life Sciences Conference


CUPERTINO, Calif., Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Lazard First Annual Life Sciences Conference. The conference is being held at Mandarin Oriental Hotel in New York, New York. Dr. Felix Theeuwes, Chairman and Chief Scientific Officer, will be presenting at the conference on Wednesday, December 1st, 2004 at 11:00 a.m. EST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

A live audio webcast of the corporate presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."

    Pain Panel: The Market Outlook

Dr. Theeuwes, will also participate in a panel discussion on chronic pain, where he will be delivering a presentation on the role of drug delivery in transforming the specialty pain market at the Lazard Life Sciences Conference, moderated by Megan Kate Murphy, Specialty Pharmaceuticals Analyst for Lazard. Also participating in the pain panel is Dr. Cynthia McCormick, former Director of FDA's Division of Anesthetic, Critical Care and Addiction Drug Products, and Dr. David Lee, EVP, Research & Development and Chief Scientific Officer for Endo Pharmaceuticals. The panel discussion will be made on Wednesday, December 1st, 2004 at 1:00 p.m. EST at Mandarin Oriental Hotel in New York, New York.

About DURECT Corporation

DURECT Corporation is a pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system) and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also partners with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which three are in collaboration with pharmaceutical partners. Additional information about DURECT is available at www.durect.com.

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of DURECT Corporation.

SOURCE DURECT Corporation

Schond L. Greenway, Executive Director, Investor Relations and Strategic Planning of DURECT Corporation, 408-777-1417
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.durect.com